ClinicalTrials.gg
CompletedNCT04752566Updated Sep 8, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome

A Phase 3 interventional study of Eculizumab and Placebo in Guillain-Barre Syndrome, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 22 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 3, prospective, multicenter, placebo controlled, double blind, randomized study to investigate the efficacy and safety of eculizumab in participants with severe GBS, defined using the Hughes Functional Grade (FG) scale as progressively deteriorating FG3 or FG4/FG5 within 2 weeks from onset of weakness due to GBS.

This study will be conducted only at sites in Japan.

Read the detailed description

Eligible participants will be randomized to receive intravenous (IV) infusion of eculizumab or placebo at a 2:1 ratio. All participants will be on concomitant IV immunoglobulin G (Ig) therapy as per standard of care.

02

Conditions studied

  • Guillain-Barre Syndrome

Keywords

  • Eculizumab
  • Soliris
  • Alexion
  • C5 Inhibition Therapy
03

In context

Guillain-Barre Syndrome

98 studies on the registry are indexed under Guillain-Barre Syndrome; 30 are open to participants now.

This study's enrollment of 57 is above the median of 50 across 44 interventional studies indexed under Guillain-Barre Syndrome.

Browse Guillain-Barre Syndrome studies →

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who meet the GBS criteria.
  • Participants who were able to run prior to onset of GBS symptoms.
  • Participants with onset of weakness due to GBS \< 2 weeks before screening.
  • Participants unable to walk unaided for ≥ 5 meters (progressively deteriorating FG3 or FG4 to FG5).
  • Participants who are already on IVIg or deemed eligible for and who will start IVIg.
  • Participants who can start their first dose of study drug before the end of the IVIg treatment period.

Exclusion criteria

Exclusion Criteria:

  • Participants who have previously received or are currently receiving treatment with complement modulators.
  • Participants who have been administered another product within 30 days or 5 half-lives (whichever is longer) prior to providing consent or are currently participating in another interventional study.
  • Participants who have received rituximab within 12 weeks prior to screening.
  • Participants who are being considered for or are already on plasmapheresis.
  • Participants who have received treatment during the 4 weeks prior to providing consent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Eculizumab

    Participants will receive eculizumab.

    Biological: Eculizumab

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • BiologicalEculizumab

    Eculizumab will be administered via IV infusion once a week for 4 weeks.

    Also known as: Soliris

  • DrugPlacebo

    Placebo will be administered via IV infusion once a week for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Time to First Reaching a Hughes Functional Grade (FG) Score <=1

    The mobility of the participants was evaluated on a 7 point disability functional grade scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 metre (m) across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. The Kaplan-Meier estimate of time to event of FG\<=1 is reported. Time (days) to first event=Date of first event-Date of first dose+1. Participants who discontinued early without achieving FG \<= 1 were censored at the date of discontinuation. Participants who completed the study without achieving FG\<=1 were censored at the date of study completion.

    Time frame: Up to Week 24

Secondary outcomes

  1. Number of Participants With A Hughes Functional Grade (FG) Score <=1

    The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. If a participant had an FG score \<= 1 prior to or at Week 8 and Week 24, respectively, then the participant is considered a responder. Otherwise, participants discontinued prior to Week 8 and Week 24 or with an FG score \> 1 at Week 8 and Week 24 are nonresponders, respectively.

    Time frame: Week 8, Week 24

  2. Number of Participants With A Hughes Functional Grade Score Improvement of >=3

    The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. Participants with a change from baseline in FG score (value at Week 24 - baseline value) \<= -3 were considered a responder. Participants with change from baseline \> -3 and participants who discontinued prior to Week 24 were considered non-responders.

    Time frame: Week 24

  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as an adverse event (AE) with onset on or after the first dose of the study drug. An AE is any untoward medical occurrence in a participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 up to Week 24

  4. Free Complement Component 5 in Serum

    Time frame: Week 24

  5. Hemolytic Complement Activity in Serum

    Time frame: Week 24

  6. Length of Stay in the Hospital

    For participants with multiple hospitalizations, the total duration of all hospitalizations was summarized.

    Time frame: Up to Week 24

  7. Number of Participants Who Required Mechanical Ventilator Support

    For participants with more than 1 episode of the same support, the total duration across all episodes was summarized.

    Time frame: Up to Week 24

  8. Concentration of Eculizumab in Serum

    Time frame: Up to Week 24

  9. Number of Participants With Positive Antidrug Antibodies

    Time frame: Up to Week 12

07

Results

Posted Feb 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneEculizumabPlacebo
Started3720
Received at least 1 dose of study drug3720
Completed3218
Not completed52
Withdrew: Protocol violation01
Withdrew: Death10
Withdrew: Adverse event10
Withdrew: Withdrawal by subject20
Withdrew: Physician decision11

Outcome measures

PrimaryTime to First Reaching a Hughes Functional Grade (FG) Score <=1

The mobility of the participants was evaluated on a 7 point disability functional grade scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 metre (m) across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. The Kaplan-Meier estimate of time to event of FG\<=1 is reported. Time (days) to first event=Date of first event-Date of first dose+1. Participants who discontinued early without achieving FG \<= 1 were censored at the date of discontinuation. Participants who completed the study without achieving FG\<=1 were censored at the date of study completion.

Time frame:
Up to Week 24
Reported as:
Median · Days
Time to First Reaching a Hughes Functional Grade (FG) Score <=1
DaysEculizumabPlacebo
Time to First Reaching a Hughes Functional Grade (FG) Score <=1112.0 (59.0 to NA)168.0 (36.0 to NA)
Statistical analysis
  • Eculizumab vs Placebo · Log Rank · p = 0.8938 (Log Rank Test stratified by randomization strata.) · Hazard ratio (hr): 0.9 · 95% CI 0.45 to 1.97Cox proportional hazard model stratified by randomization strata, with treatment group as the fixed effect. Firth's adjustment was applied if no event was observed in a treatment group.
SecondaryNumber of Participants With A Hughes Functional Grade (FG) Score <=1

The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. If a participant had an FG score \<= 1 prior to or at Week 8 and Week 24, respectively, then the participant is considered a responder. Otherwise, participants discontinued prior to Week 8 and Week 24 or with an FG score \> 1 at Week 8 and Week 24 are nonresponders, respectively.

Time frame:
Week 8, Week 24
Reported as:
Count of participants · Participants
Number of Participants With A Hughes Functional Grade (FG) Score <=1
ParticipantsEculizumabPlacebo
Week 8127
Week 242013
Statistical analysis
  • Eculizumab vs Placebo · Regression, Logistic · p = 0.8987 · Odds ratio (or): 0.9 · 95% CI 0.27 to 3.17
  • Eculizumab vs Placebo · Regression, Logistic · p = 0.4083 · Odds ratio (or): 0.6 · 95% CI 0.18 to 2.02
SecondaryNumber of Participants With A Hughes Functional Grade Score Improvement of >=3

The mobility of the participants was evaluated on a 7 point disability FG scale and described as Hughes FG score of 0 (Healthy, no signs or symptoms of Guillain-Barré syndrome); 1 (Minor signs or symptoms and able to run); 2 (Able to walk 5 m across an open space without assistance); 3 (Able to walk 5 m across an open space with the help of one person and waist-level walking-frame, stick, or sticks); 4 (Chairbound/bedbound: unable to walk as in 3); 5 (Requiring assisted ventilation \[for at least part of day or night\]) and 6 (Dead), where higher numbers indicate more severe impairment. Participants with a change from baseline in FG score (value at Week 24 - baseline value) \<= -3 were considered a responder. Participants with change from baseline \> -3 and participants who discontinued prior to Week 24 were considered non-responders.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With A Hughes Functional Grade Score Improvement of >=3
ParticipantsEculizumabPlacebo
Number of Participants With A Hughes Functional Grade Score Improvement of >=31610
Statistical analysis
  • Eculizumab vs Placebo · Regression, Logistic · p = 0.6739 · Odds ratio (or): 0.8 · 95% CI 0.24 to 2.54
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as an adverse event (AE) with onset on or after the first dose of the study drug. An AE is any untoward medical occurrence in a participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsEculizumabPlacebo
Number of Participants With Treatment-emergent Adverse Events (TEAEs)3419
SecondaryFree Complement Component 5 in Serum
Time frame:
Week 24
Reported as:
Mean · micrograms/milliliters
Free Complement Component 5 in Serum
micrograms/millilitersEculizumabPlacebo
Free Complement Component 5 in Serum131.0438 ± 29.40068147.8833 ± 36.70182
SecondaryHemolytic Complement Activity in Serum
Time frame:
Week 24
Reported as:
Mean · percentage of hemolysis
Hemolytic Complement Activity in Serum
percentage of hemolysisEculizumabPlacebo
Hemolytic Complement Activity in Serum91.79 ± 11.07791.83 ± 11.767
SecondaryLength of Stay in the Hospital

For participants with multiple hospitalizations, the total duration of all hospitalizations was summarized.

Time frame:
Up to Week 24
Reported as:
Mean · days
Length of Stay in the Hospital
daysEculizumabPlacebo
Length of Stay in the Hospital49.5 ± 27.1539.8 ± 12.97
SecondaryNumber of Participants Who Required Mechanical Ventilator Support

For participants with more than 1 episode of the same support, the total duration across all episodes was summarized.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Required Mechanical Ventilator Support
ParticipantsEculizumabPlacebo
Number of Participants Who Required Mechanical Ventilator Support81
SecondaryConcentration of Eculizumab in Serum
Time frame:
Up to Week 24
Reported as:
Mean · micrograms/milliliters
Concentration of Eculizumab in Serum
micrograms/millilitersEculizumab
Concentration of Eculizumab in Serum4.690 ± 0.0000
SecondaryNumber of Participants With Positive Antidrug Antibodies
Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Positive Antidrug Antibodies
ParticipantsEculizumabPlacebo
Number of Participants With Positive Antidrug Antibodies00

Adverse events

Collected over Day 1 up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eculizumab1/37 (2.7%)4/37 (10.8%)34/37 (91.9%)
Placebo0/20 (0%)1/20 (5%)18/20 (90%)
Most frequent serious events
Most frequent serious events
EventEculizumabPlacebo
Pneumonia aspirationInfections and infestations2/370/20
Chronic inflammatory demyelinating polyradiculoneuropathyNervous system disorders0/371/20
HangingGeneral disorders1/370/20
COVID-19Infections and infestations1/370/20
Most frequent other events
Showing 10 of 65
Most frequent other events
EventEculizumabPlacebo
InsomniaPsychiatric disorders10/378/20
ConstipationGastrointestinal disorders4/377/20
Urinary tract infectionInfections and infestations5/373/20
Aspartate aminotransferase increasedInvestigations2/373/20
Alanine aminotransferase increasedInvestigations1/373/20
HyponatraemiaMetabolism and nutrition disorders0/373/20
HeadacheNervous system disorders5/373/20
Dermatitis contactSkin and subcutaneous tissue disorders3/373/20
DiarrhoeaGastrointestinal disorders5/371/20
PyrexiaGeneral disorders5/370/20

Baseline characteristics

Full analysis set included all randomized participants who received at least 1 dose of study drug and had a baseline functional grade (FG) score and at least 1 postbaseline FG score.

Age, Continuous
Age, Continuous(years)EculizumabPlaceboTotal
Mean56.6 ± 19.6156.2 ± 18.3456.4 ± 19.01
Sex: Female, Male
Sex: Female, Male(Participants)EculizumabPlaceboTotal
Female19524
Male181533
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EculizumabPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino372057
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EculizumabPlaceboTotal
American Indian or Alaska Native000
Asian372057
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

22 sites
  • Research Site
    Bunkyō City, 113-8519, Japan
  • Research Site
    Chiba, 260-0877, Japan
  • Research Site
    Fukuoka, 814-0180, Japan
  • Research Site
    Hiroshima, 730-8518, Japan
  • Research Site
    Kagoshima, 890-8520, Japan
  • Research Site
    Kawagoe-shi, 350-8550, Japan
  • Research Site
    Kawasaki-shi, 216-8511, Japan
  • Research Site
    Kitakyushu-shi, 807-8555, Japan
  • Research Site
    Kobe, 650-0047, Japan
  • Research Site
    Kumamoto, 860-8556, Japan
  • Research Site
    Kurashiki-shi, 710-8602, Japan
  • Research Site
    Matsumoto-shi, 390-8621, Japan
  • Research Site
    Mitaka-shi, 181-8611, Japan
  • Research Site
    Nagoya, 466-8560, Japan
  • Research Site
    Niigata, 951-8520, Japan
  • Research Site
    Nishinomiya-shi, 663-8501, Japan
  • Research Site
    Sapporo, 060-8648, Japan
  • Research Site
    Sayama, 589-8511, Japan
  • Research Site
    Sendai, 983-8520, Japan
  • Research Site
    Shimotsuga-gun, 321-0293, Japan
  • Research Site
    Ube-shi, 755-8505, Japan
  • Research Site
    Yokohama, 236-0004, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Aug 2022, 16 months.

Results were first posted in Feb 2024, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 12, 2021
StartActual
Mar 8, 2021
Primary completionActual
Aug 3, 2022
CompletionActual
Aug 3, 2022
Results first posted
Feb 9, 2024
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04752566
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
Mar 8, 2021
Primary completion
Aug 3, 2022
Completion
Aug 3, 2022
Results posted
Feb 9, 2024
Last update
Sep 8, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion